<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893658</url>
  </required_header>
  <id_info>
    <org_study_id>12-006797</org_study_id>
    <nct_id>NCT01893658</nct_id>
  </id_info>
  <brief_title>Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)</brief_title>
  <official_title>Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute
      Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of
      prednisone for treatment of drug-induced AIN. Currently there is no good treatment for
      drug-induced AIN. Prednisone is the standard treatment but is associated with many
      side-effects when used long-term and at high doses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>Baseline to three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean individual percentage drop in serum creatinine relative to entry creatinine levels</measure>
    <time_frame>baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects returning to their usual baseline creatinine (+25%) or below</measure>
    <time_frame>baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Neutrophil gelatinase-associated lipocalcin.</measure>
    <time_frame>baseline to 3 months</time_frame>
    <description>24 hours, 4 hours, and in 3 months after Xolair treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring renal replacement therapy</measure>
    <time_frame>baseline to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Interstitial Nephritis</condition>
  <arm_group>
    <arm_group_label>Omalizumab and Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone
Standard clinical therapy with prednisone.
Day 1-14: 60 mg/day 14 days (2 weeks)
Day 15-28: 40 mg/day (2 weeks)
Day 29-35: 30 mg/day (1 week)
Day 36-42: 20 mg/day (1 week)
Day 43-49: 10 mg/day (1 week)
Day 50-56: 5 mg/day (1 week)
Subjects will stop taking prednisone on day 57
If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard clinical therapy with prednisone.
Day 1-14: 60 mg/day 14 days (2 weeks)
Day 15-28: 40 mg/day (2 weeks)
Day 29-35: 30 mg/day (1 week)
Day 36-42: 20 mg/day (1 week)
Day 43-49: 10 mg/day (1 week)
Day 50-56: 5 mg/day (1 week)
Subjects will stop taking prednisone on day 57
If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>administration of a single dose together with the standard treatment</description>
    <arm_group_label>Omalizumab and Prednisone</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>standard treatment</description>
    <arm_group_label>Omalizumab and Prednisone</arm_group_label>
    <arm_group_label>Prednisone</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult subjects &gt; 18 years old of both genders

          2. Biopsy proven acute interstitial nephritis in the native kidneys without evidence of
             ischemic or glomerular pathology in the biopsy

          3. Normal baseline creatinine defined as estimated GFR ≥ 60 ml/min/SA based on MDRD
             calculation within 1 year prior to renal biopsy

          4. Serum creatinine elevation of &gt; 0.3 mg/dL and/or doubling of serum creatinine compared
             to most recent documented creatinine available (at least within the last year)

          5. No immunosuppressants in the last three months including prednisone

          6. Women of childbearing potential not using the contraception method can be included as
             this is a one time dosing and has no known long-term effects.

        Exclusion Criteria:

          1. Unwillingness to give consent

          2. Patients who are Pregnant (positive serum pregnancy test for females) or breast
             feeding

          3. Documented history of an autoimmune disease

          4. Inability or unwillingness to take prednisone for the prescribed duration and/or dose

          5. Subjects suspected to have non-drug-induced AIN

          6. Subjects not meeting the inclusion criteria

          7. Subjects with contraindication to administration of omalizumab

          8. Prior use of omalizumab

          9. Severe hypersensitivity to omalizumab or any component of the product

         10. Known elevated IgE level from other disease processes

         11. Subjects taking (nonsteroidal antiinflammatory drug) NSAIDs chronically

         12. Use of any other investigational agents in the last 30 days

         13. Patients with severe medical condition(s) including metastatic cancer, terminal
             congestive heart failure, severe ischemic heart disease or any other medical condition
             in which life expectancy is less than 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vesna D. Garovic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne D. Ryan</last_name>
    <phone>507-266-8668</phone>
    <email>ryan.joanne@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen S Mieras, CCRP</last_name>
    <phone>507-284-9187</phone>
    <email>mieras.kathleen@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne D. Ryan</last_name>
      <phone>507-266-8668</phone>
      <email>ryan.joanne@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen S. Mieras, CCRP</last_name>
      <phone>507-284-9187</phone>
      <email>mieras.kathleen@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ladan Zand, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaiser Lim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vesna D. Garovic, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Vesna D. Garovic, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Interstitial Nephritis</keyword>
  <keyword>Nephritis</keyword>
  <keyword>Tubulointerstitial</keyword>
  <keyword>Renal disease</keyword>
  <keyword>Kidney</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Nephritis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

